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Abstract 28 
Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies that arise in the biliary 29 
tree within and outside the liver. Beyond surgical resection, which is beneficial for only a small 30 
proportion of patients, current strategies for treating patients with BTCs include chemotherapy, as 31 
single agent or combination regimens, in the adjuvant and palliative setting. Increased 32 
1haracterization of the molecular landscape of these tumours has facilitated the identification of 33 
molecular vulnerabilities, such as IDH mutations and FGFR fusions, that can be exploited for the 34 
treatment of BTC patients. Beyond targeted therapies, active research avenues explore the 35 
development of novel therapeutics that target the crosstalk between cancer and stroma, the cellular 36 
pathways involved in the regulation of  cell death, the chemoresistance phenotype and the 37 
dysregulation of RNA. In this review we  discuss the therapeutic opportunities currently available in 38 
the management of BTC patients, and we explore the strategies that can support the implementation 39 
of precision oncology in BTCs, including novel molecular targets, liquid biopsies and patient-derived 40 
predictive tools. 41 
 42 
Background  43 
 44 
Biliary tract cancers (BTCs) comprise a group of rare and aggressive malignancies that arise in the 45 
biliary tree, a complex system of ducts accounting for the modification and transfer of bile from the 46 
canaliculi, where it is initially generated, to the duodenum. 47 
BTCs include cholangiocarcinoma (CCA), gallbladder cancer (GBC) and ampulla of Vater cancer 48 
(AVC). The studies mentioned in this manuscript often include a combination of all biliary cancers. 49 
More recently, dedicated trials to CCAs without GBCs and AVC are being conducted. Biliary 50 
ampullary cancers are rare tumours and to date no dedicated trials have been set up, so their 51 
management follows the indication of the rest of BTCs.   52 
According to the updated anatomical classification, CCA can be further subdivided into intrahepatic 53 
(iCCA), perihilar (pCCA) and distal (dCCA) cholangiocarcinoma, which also reflect differences in 54 
epidemiology, aetiology, embryology, biology, prognosis and strategy for clinical management (1). 55 
Based on previous data, CCA has also been classified as iCCA, originating from the biliary tree 56 
within the liver, and extrahepatic cholangiocarcinoma (eCCA), which occurs outside the liver 57 
parenchyma, and includes perihilar and distal ducts. 58 
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Comprehensively, BTCs represent 3% of all gastrointestinal cancers and are the second most common 59 
type of primary liver cancer after hepatocellular carcinoma (2). Worldwide, the incidence and 60 
mortality of BTCs are rising (2–4). Although incidence is much higher in Eastern countries (up to 85 61 
per 100,000 in Thailand) compared to the rest of the world due to the liver flukes, studies show that 62 
CCA rates are rising in most western countries. In the United States, a country with one of the lowest 63 
incidence rate, BTC incidence increased with an annual percentage change of 4.36% in the last 64 
decade reaching a value of 1.6 per 100,000 (5). 65 
Multiple risk factors are known to be associated with BTC development, including liver fluke, biliary 66 
tract disorders, chronic liver diseases and metabolic syndrome (3,6).  67 
BTCs are characterised by clinical and pathological heterogeneity, showing a poor response to 68 
chemotherapy and dismal prognosis. Due to the asyntomatic behaviour of the disease, most of patients 69 
with BTCs are diagnosed at advanced stage. Only patients with localised disease (20%) benefit from 70 
surgical resection. However, the recurrence rate is very high, with a median 5-year survival of <50% 71 
in resected patients (7). For patients with advanced unresectable or metastatic BTCs (approximately 72 
60-80%) systemic therapies are the only potential therapeutic options and the median overall survival 73 
(mOS) is poor, ranging from 6 to18 months (8). 74 
In an attempt to improve the clinical outcome of patients with BTCs, shared efforts are moving 75 
towards two goals: the identification of molecular alterations and prognostic factors that can guide 76 
treatment; and the development of novel therapeutics and combination strategies. We begin this 77 
review by outlining the currently available therapeutic strategies for BTC patients before discussing 78 
personalised oncology as an approach for the management of these  patients.  79 
 80 
 81 
Systemic therapy for cholangiocarcinoma: where do we stand? 82 
 83 
Adjuvant therapy  84 
The incidence of locoregional and distant relapse remains high in patients with resected BTCs. Until 85 
2017, the use of adjuvant treatment was based on meta-analysis data from small and retrospective 86 
phase II studies showing an improvement in OS in two high-risk populations: those with node-87 
positive disease and those with R1 resection (9). Subsequently, the results of three prospective 88 
randomised clinical trials (RCTs) exploring experimental adjuvant chemotherapy arms in resected 89 
BTC patients have been published (10–12). In the Japanese BCAT trial (10), 226 patients with eCCA 90 
were randomly assigned to gemcitabine or observation alone following surgery. The study did not 91 
meet its primary endpoint, with no significant differences in mOS (62.3 versus 63.8 months, 92 
respectively; HR 1.01, 95 % CI 0.70 to 1.45; p = 0.964) or relapse-free survival (RFS; median 36.0 93 
versus 39.9 months; HR 0.93, 95 % CI 0.66 to 1.32; p = 0.693) between the two groups. The French 94 
PRODIGE-12/ACCORD-18 study (11) also failed to show a benefit in response to the adjuvant 95 
combination of gemcitabine and oxaliplatin (GEM/OX) compared with observation alone in patients 96 
following resection of CCA and GBC; this study did not meet its primary endpoint, with no benefit in 97 
terms of RFS in the doublet-chemo arm (30.4 months versus 18.5 months in observational arm; HR 98 
0.88; 95% CI, 0.62 to 1.25; p = 0.48). The BILCAP study (12), conducted in the UK over a period of 99 
9 years, is the largest study so far involving patients with CCA and patients with GBC. Although the 100 
study did not meet its primary endpoint in terms of OS in the intention-to-treat population (ITT), the 101 
pre-specified ITT sensitivity analysis adjusted for prognostic factors (nodal status, grade of disease 102 
and gender) and the per-protocol population analysis did show a longer mOS in the capecitabine arm 103 
(53 months versus 36 months in the observational arm, HR 0.75, 95% CI 0.58-0.97; p = 0.028). In the 104 
ITT analysis, median RFS was longer with capecitabine (24.4 months, 95% CI 18.6-35.9) compared 105 
with observation (17.5 months, 95% CI 12.0-23.8), but no differences in the risk of relapse were 106 
demonstrated after 24 months.  107 
As well as differences in BTC subtypes, heterogeneity in the populations enrolled in these three 108 
adjuvant trials with regards to node involvement and resection margins should be noted (13). The 109 
higher proportion of patients with poor prognostic factors could partly explain why the BILCAP trial 110 
is the only study that demonstrates a beneficial effect of adjuvant chemotherapy in patients with 111 
resected BTCs. Importantly, it should be noted that the three RCTs differ in sample size calculation, 112 
statistical power of study design, maturity of data and follow-up time. Future efforts in designing 113 
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multicentre, randomised phase III trials should aim to standardise risk factors and include them in pre-114 
planned analyses to obtain a more optimal patient selection and study design. The largest ongoing 115 
study evaluating the efficacy of adjuvant therapy in patients with BTC is the ACTICCA study, which 116 
compares gemcitabine and cisplatin chemotherapy (GEM/CIS) to capecitabine alone 117 
(ClinicalTrials.gov: NCT02170090).  118 
 119 
First-line chemotherapy 120 
Gemcitabine plus cisplatin is currently the standard first-line treatment for patients with advanced 121 
BTC (aBTC), based on the results of Advanced Biliary Tract Cancer (ABC-02) phase III and the 122 
Japanese BT22 phase II trials, which demonstrated the superiority of this combination compared with 123 
gemcitabine monotherapy (14,15).  124 
However, to improve further on the modest survival benefit conferred by GEM/CIS, other first-line 125 
chemotherapy options are under investigation. The FUGA-BT trial reported non-inferiority of 126 
gemcitabine plus S-1 (a fluoropyrimidine derivative) chemotherapy compared with GEM/CIS, 127 
suggesting that this treatment could represent another option for aBTC (16). Furthermore, a phase II 128 
study evaluating nanoliposomal-irinotecan in combination with 5-FU/Leucovorin versus GEM/CIS is 129 
ongoing (17). Beyond doublet therapy, a phase II triplet approach with nanoparticle albumin-bound 130 
(nab)-paclitaxel plus GEM/CIS attained the highest mOS (19.2 months) reported in this setting (18); 131 
this combination is currently under evaluation in a randomised phase III study versus GEM/CIS 132 
(S1815 SWOG clinical trial). 133 
A 2020 post-hoc analysis of results from prospective, randomly assigned ABC-01/02/03 trials of 134 
GEM/CIS shows a longer OS (by ~4 months) of patients with iCCA compared with non-iCCA-BTC 135 
patients and suggests — albeit with a low level of evidence due to the small size — a more favourable 136 
prognosis of iCCA and iCCA with liver-only disease (19). Such a difference might be of relevance 137 
when assessing the suitability of sequential liver-directed therapies on the OS of these patients. Two 138 
phase II trials combining gemcitabine and platinum derivatives with concomitant liver-directed 139 
therapies (radioembolisation with yttrium-90 [a technique in which microspheres emit β-radiation to 140 
block the supply of blood to the tumour] and intra-arterial infusion) yielded interesting median OS 141 
figures (22 and 25 months, respectively) (20,21). Confirmatory phase III studies of radioembolization 142 
are awaited. 143 
When evaluating OS, it is also important to consider the impact of prognostic factors (also relevant 144 
for patient stratification). The post-hoc analysis of GEM/CIS pivotal trials (14,15,19) suggests a 145 
prognostic role for Eastern Cooperative Oncology Group (ECOG) performance status (PS), white 146 
blood cells, haemoglobin, disease status, bilirubin, neutrophil count and gender, but these data have 147 
not yet been confirmed (19). In a real life setting, a study conducted by the G.I.Co. (Italian Group of 148 
Cholangiocarcinoma) involving 940 Italian patients with aBTC captures ECOG, prior resection, 149 
tumour grading, baseline carcinoembryonic antigen and carbohydrate antigen 19.9 as factors that are 150 
independently associated with OS (22). Further studies incorporating putative molecular prognostic 151 
factors such as the fibroblast growth factor receptor (FGFR)-2 fusions are needed to identify genomic 152 
prognostic variables that might help to identify prognosis and predict treatment outcomes. 153 
 154 
Second-line chemotherapy 155 
The benefit of any second-line treatment for patients with BTC has been unclear until the past year. A 156 
systematic review published in 2014 showed that studies available in the second-line setting were of 157 
limited quality, with 14 out of 25 eligible studies representing phase II clinical trials and no RCTs 158 
being identified (23). Data from a total of 761 individual patients were reported; the pooled mOS, 159 
PFS, response rate (RR) and disease control rate (DCR) were 7.2 months (95% CI 6.2–8.2), 3.2 160 
months (95% CI 2.7–3.7), 7.7% (95% CI 4.6–10.9) and 49.5% (95% CI 41.4–57.7), respectively. 161 
Although the available data suggested that a subpopulation of patients, especially young patients and 162 
those with a good PS, could benefit from second-line chemotherapy, this benefit number seemed 163 
limited and the evidence was considered to be of insufficient quality (level C) to recommend second-164 
line chemotherapy for aCCA as a standard of care strategy (24). One of the main challenges for the 165 
completion of adequately powered studies was the fact that, due to the aggressive behaviour of CCA, 166 
few patients (ranging from 10 to 40% in different series) are considered to be eligible for second-line 167 
treatment (22,25–28). In 2019, results from the ABC-06 clinical trial were reported (29). This phase 168 
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III study recruited 162 patients diagnosed with aBTC (72% of whom had a diagnosis of CCA) 169 
following progression on first-line GEM/CIS chemotherapy. Patients were randomly assigned to 170 
active symptom control (ASC; 81 patients) or ASC with FOLFOX (5-fluorouracil and oxaliplatin; 81 171 
patients). The study met its primary endpoint, showing a benefit from second-line chemotherapy in 172 
terms of OS (adjusted HR 0.69 [95% CI 0.50-0.97]; p = 0.031). Even though absolute differences in 173 
mOS were modest (5.3 months [ASC arm] versus 6.2 months [ASC+FOLFOX arm]), differences in 174 
the survival rate at 6 months (35.5% [ASC arm] versus 50.6% [ASC+FOLFOX arm]) and 12 months 175 
(11.4% [ASC arm] versus 25.9% [ASC+FOLFOX arm]) were clinically meaningful. Therefore, 176 
FOLFOX is currently being considered as standard of care second-line chemotherapy for patients 177 
with aBTC previously-treated with GEM/CIS.  178 
Novel chemotherapy strategies, such as FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) 179 
(30) and etoposide toniribate (EDO-S7.1) (31) are being tested in the second-line setting, but their 180 
efficacy requires confirmation. The phase II studies NALIRICC (ClinicalTrials.gov: NCT03043547) 181 
and NAPOLI-2 (ClinicalTrials.gov: NCT04005339) are currently assessing the nanoliposomal-182 
irinotecan/5-FU/leucovorin versus 5-FU/leucovorin in patients previously treated with gemcitabine-183 
based therapies. 184 
 185 
Targeted therapies on the horizon  186 
The molecular landscape of BTCs has begun to emerge over the past decade, offering researchers and 187 
clinicians the potential to develop novel molecularly-targeted therapies (32) (Table 2). Accordingly, 188 
molecular profiling of CCA tumours has become increasingly significant over the past years due to 189 
the identification of potentially druggable molecular alterations, such as mutations in IDH1/2 and 190 
FGFR2 fusions (33). Mutations in IDH1/2 disrupt the normal catalytic activity of isocitrate 191 
dehydrogenase 1/2, causing the altered protein to produce a new metabolite 2-hydroxyglutarate (2-192 
HG), which induces several oncogenic changes to cellular metabolism. FGFR2 fusions contain the 193 
intact kinase domain fused to a large number of different partners, including BICC1, AHCYL1, 194 
TACC3, MGEA5 and PPHLN1 (34–40), leading to the constitutive activation of the FGFR2 fusion 195 
protein (FFP) and its consequent downstream oncogenic pathways (39). The would-be therapeutic 196 
effect of acting on these potentially targetable alterations is currently being evaluated.  197 
In the ClarIDHy phase III trial, 185 patients with IDH1-mutant CCA following progression on 198 
standard of care chemotherapy were randomised to receive the IDH1 inhibitor ivosidenib or placebo. 199 
The primary endpoint was met, with a median PFS of 2.7 versus 1.4 months for patients receiving 200 
ivosidenib and for placebo group, respectively (HR, 0.37; 95% CI, 0.25-0.54; p <.001). ITT analysis 201 
revealed a mOS of 10.8 months in the experimental group versus 9.7 months in the placebo group 202 
(41). Ongoing clinical trials are also exploring the efficacy of PARP inhibitors in IDH1/2 mutant 203 
iCAA (as IDH1 mutations render tumours sensitive to PARP inhibition) in order to assess their 204 
synthetic lethality and to target IDH1/2-related dependencies (ClinicalTrials.gov: NCT03212274, 205 
NCT03878095). 206 
Phase II clinical trials showed meaningful clinical benefits of FGFR inhibitors in the treatment of 207 
chemorefractory iCCA patients carrying FGFR2 fusions, which constitute the most clinically 208 
responsive group of patients. In a phase II trial assessing the pan FGFR inhibitor BGJ398/infigratinib 209 
(42), the objective response rate (ORR) and disease control rate (DCR) were 18.8% and 83.3%, 210 
respectively, while another pan FGFR inhibitor, ARQ087/Derazantinib, resulted in an ORR and DCR 211 
of 20.7% and 82.8%, respectively, in a phase II trial (43). The FIGHT-202 study tested the FGFR1–3 212 
inhibitor pemigatinib in 107 patients with FGFR2 fusions, obtaining an impressive 35.5% ORR, with 213 
a median duration of response of 7.5 months and PFS of 6.9 months (44). Currently there are several 214 
FGFR inhibitors that differ with respect to their toxicity and specificity through the target range 215 
(FGFR1–4 ) under clinical investigation, including Debio 1347, TAS-120/Futibatinib and erdafitinib 216 
(42,43,45–48) (Table 1). Infigratinib, pemigatinib and futibatinib have progressed to phase III 217 
evaluation as first-line single agents versus the standard of care GEM/CIS (ClinicalTrials.gov: 218 
NCT03773302, NCT03656536, NCT04093362), with the trial results eagerly awaited (49). 219 
 220 
Novel opportunities for targeted therapeutics in biliary cancer 221 
 222 
Is there more to know about FGFR2-aberrant tumours?  223 
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FGFR2 fusion transcripts generated by chromosomal rearrangements are found in about 10–15% of 224 
patients with iCCA (34,36,37,50,51). The efficacy of first-generation tyrosine kinase inhibitors (F-225 
TKIs) in iCCA patients is limited by the emergence of secondary resistance, a major genetic 226 
determinant of which is represented by on-target mutations that prevent access of F-TKIs to the 227 
FGFR2 ATP-binding pocket (52,53). Resistance mutations in FFPs are most often polyclonal (52–228 
54). In vitro experiments delineated a drug sensitivity profile of individual FFP mutants congruent 229 
with clinical data: thus, while some mutations cause cross-resistance among different F-TKIs (e.g. 230 
N550K, L618V and K660M mutations reduce binding to both BGJ398 and Debio 1347), others 231 
appear to be drug-specific (e.g. M538I impairs binding of Debio 1347, but not BGJ398) (53). 232 
Interestingly, TAS-120 maintains activity against most resistance mutations detected so far in 233 
BGJ398-treated patients, but lacks efficacy against the highly prevalent V565F gatekeeper mutation 234 
(52,53); Debio 1347, on the other hand, loses activity against most resistance mutations, except 235 
V565F (53). 236 
Rapidly evolving polyclonal FFP mutations represent a clinical challenge. Sequential administration 237 
of mutant-specific F-TKIs informed by next-generation sequencing analysis of circulating tumour 238 
DNA has been advocated, but its benefit appears to be limited given the emergence of several clones 239 
(53). An alternative strategy could be to prevent the emergence of resistance mutations by upfront 240 
combination therapies that incorporate, in addition to the F-TKI of choice, agents that are capable of 241 
targeting dependencies shared by wild-type and TKI-resistant FFPs. FFPs, including those with 242 
resistance mutations, are heat shock protein 90 (HSP90) clients and are therefore stabilised by these 243 
chaperones; as such, they undergo swift degradation upon HSP90 inhibition (55). Moreover, F-TKIs 244 
and HSP90 inhibitors exert synergistic effects against FFP-transformed cells (55). Notably, as latest-245 
generation HSP90 inhibitors lack the liver and ocular toxicities that have limited the clinical 246 
development of earlier drugs in this class (56), they might therefore deserve consideration in the 247 
iCCA field (57). Along this line, an emerging paradigm postulates that therapeutic targeting of a 248 
driver kinase is more efficacious when combined with the blockade of downstream pathway 249 
components (58,59). 250 
 251 
 252 
Other actionable alterations in CCA  253 
With the advent of improved technologies, it has become apparent that there are multiple potentially 254 
actionable alterations in BTCs. In addition to FGFR2 fusions and IDH1 mutations, many other 255 
alterations, such as amplification of the receptor tyrosine kinase c-MET, targetable with savolitinib 256 
(60), and overexpression of the epidermal growth factor receptor (EGFR) (61), require clinical 257 
evaluation, although this will always be challenging because of the low number of patients with these 258 
changes. Other important events that require further investigation include activation of the Janus 259 
kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway through 260 
constitutive activation of STAT3, which is estimated to occur in 58–77% of patients with iCCA 261 
(depending on inflammation or proliferation biological class, respectively) (62), and gain-of-function 262 
mutations in protein tyrosine phosphatase non-receptor type 3 (PTPN3), which have been reported in  ̴ 263 
41% of patients (63). Moreover, it remains to be seen whether therapeutically inhibiting additional 264 
promising targets, such as HER2 (64,65), BRAF (66) and BRCA, (67) confers a similar benefit to that 265 
observed in more common cancers such as breast (HER2), melanoma (BRAF) and ovarian 266 
malignancies (BRCA). Preliminary data from patients with HER2-positive aBTC have shown that dual 267 
HER2-targeted treatment with pertuzumab and trastuzumab has activity in this setting (68). The 268 
combination of BRAF and MEK inhibitors was also tested in a phase I trial and showed promising 269 
results for CCA patients with the activating BRAF V600E mutation (66). 270 
Nevertheless, there remains a large cohort ( ̴ 50%) of patients with no currently actionable alteration. 271 
For instance, some of the most frequent genetic mutations in CCA comprise the proto-oncogene 272 
KRAS and the tumour suppressor TP53, for which the options are limited (Table 3). To date, despite 273 
the large number of potential therapeutic targets identified by molecular profiling, more advanced 274 
genomic technologies might be required to reveal novel actionable alterations in these difficult-to-275 
treat cancers. 276 
Mutations in DNA damage repair (DDR) genes are present in about 20% of BTCs, especially in 277 
extrahepatic BTCs. In these tumours, PARP inhibitors may have a therapeutic role as they counteract 278 
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the activity of the PARP enzyme to repair single strand DNA breaks. However, the benefit of olaparib 279 
monotherapy has been limited in other gastrointestinal cancers (69); thus, it is likely that combination 280 
treatments will be explored in BTC. PARP inhibitors may be combined with immunotherapy (see 281 
below), with antiangiogenic therapies (given that hypoxia can reduce DDR), or PI3K/MEK inhibitors 282 
(that are over-activated in BTC and have been associated to secondary resistance to PARP inhibition) 283 
(70). 284 
Epigenetic alterations have also been described in BTCs (71). Treatments aimed at reversing these 285 
changes have been studied and shown to be promising, such as the histone deacetylase (HDAC) 286 
inhibitor resminostat in pretreated BTC patients (72). 287 
 288 
Immunotherapy: only for the few? 289 
In contrast to the promising data observed with targeted therapies in molecularly-defined patients, 290 
immunotherapy (given as a monotherapy) has so far been disappointing in patients with anatomically 291 
and molecularly uncharacterised aBTC. One of the largest published immunotherapy studies ever is 292 
the KEYNOTE-158 phase II clinical trial, which assessed the efficacy of pembrolizumab, an antibody 293 
that targets the immune checkpoint protein programmed death-1 (PD-1), in patients with previously-294 
treated solid tumours, including those of the biliary tract. The subgroup analysis of 104 patients with 295 
aBTC treated with pembrolizumab revealed a response rate (RR) of 5.8% with a median PFS of 2 296 
months and a mOS of 9.1 months regardless of PD-L1 positivity (membranous PD-L1 expression in 297 
≥1%of tumours and associated inflammatory cells or positive staining in stroma) (73). Consistent with 298 
other studies, pembrolizumab showed durable anti-tumour activity among the few responsive patients.  299 
So far, a high degree of microsatellite instability [MSI-High (H)], occurring in 1–3% of CCA patients 300 
(with germline mutations in mismatch repair genes), is the only marker that appears to be predictive 301 
of clinical response to immunotherapy. The KEYNOTE-158 study evaluating pembrolizumab in 302 
previously-treated patients with advanced non-colorectal MSI-H/deficient mismatch repair (dMMR) 303 
cancer showed an ORR of 40.9%, median PFS of 4.2 months, and mOS of 24.3 months in the BTC 304 
cohort of 22 patients (74), demonstrating a clinical benefit of pembrolizumab among these patients, 305 
consistent with results from other patients with previously treated MSI-H/dMMR noncolorectal 306 
cancer assessed in the study.  307 
In order to increase the efficacy of immunotherapy in BTCs, different therapeutic combinations are 308 
currently being tested (Table 4). One approach includes the combination of immunotherapy and 309 
chemotherapy. Early clinical data from the combination of nivolumab with GEM/CIS as a first-line 310 
treatment showed signs of antitumour activity, with a RR of 37%, a median PFS of 4.2 months and 311 
mOS of 15.4 months (75). This concept of immunotherapy–chemotherapy combination is currently 312 
further evaluated in phase III studies such as TOPAZ-1 and KEYNOTE-966, in which patients are 313 
being treated with GEM/CIS alone or with durvalumab (which targets PD-L1, the PD-1 ligand) or 314 
pembrolizumab, respectively. 315 
The use of immunotherapy together with anti-angiogenic agents has shown high efficacy against 316 
hepatocellular carcinoma, but has not so far been successful in the treatment of BTC. In one study, 317 
pembrolizumab plus ramucirumab, which inhibits vascular-endothelial growth factor (VEGF)-318 
induced angiogenesis, showed limited efficacy in patients with previously treated advanced/metastatic 319 
BTC (only 4% in 26 patients), with a mOS of 6.4 months and median PFS of 1.6 months (76). Similar 320 
to VEGF signalling, targeting the transforming growth factor β (TGF-β) pathway has been shown to 321 
promote tumour immunosuppression and, based on encouraging efficacy observed in a phase I study, 322 
M7824, a first-in-class bifunctional fusion protein comprising two extracellular domains of TGF-βRII 323 
(a TGF-β ‘trap’) fused to a human IgG1 monoclonal antibody against PD-L1, is currently being 324 
evaluated in combination with GEM/CIS as a first-line therapy for BTC (clinical trial.gov: 325 
NCT04066491). Moreover, the immunogenicity resulted from the increased mutational burden (and 326 
thus the neoantigenes) caused by the mechanism of action of PARP inhibitors has provided the 327 
rationale to assess them with immunotherapy (clinical trial.gov: NCT03639935). 328 
 329 
 330 
Potential opportunities to reverse chemoresistance in biliary cancers 331 
 332 
The molecular mechanisms of chemoresistance  333 
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The mechanisms of chemoresistance to anticancer drugs (77–79), which are classified into seven 334 
groups (Figure 1), can already be present in tumours before the start of treatment (primary resistance), 335 
although they usually arise in response to the pharmacological challenge (secondary resistance). Drug 336 
resistance occurs due to changes in the expression levels or/and the appearance of genetic variants in 337 
genes encoding mechanisms of chemoresistance (80).  338 
Several transporters play a role in resistance by influencing the bioavailability of drugs, both 339 
positively and negatively. For instance, upregulation of the human equilibrative nucleoside transporter 340 
1 (hENT1) in CCA cells is associated with a better response to gemcitabine in patients with resected 341 
CCA (81) and aBTC (82), and impaired expression of the organic cation transporter 1 (OCT1) is 342 
thought to mediate the poor response to cisplatin and the multikinase inhibitor sorafenib (83,84). By 343 
contrast, ATP-binding cassette proteins, such as MDR1, MRP1 and MRP3, which are highly 344 
expressed in CCA, are able to export a wide variety of anti-tumour drugs out of cells, thereby limiting 345 
their effect. Interestingly, high MRP1 mRNA levels correlate inversely with OS after the treatment of 346 
iCCA (85). Chemical modification of some conventional chemotherapy drugs has enabled these 347 
compounds to enter the cancer cell independently of the above mentioned membrane transporters and 348 
may represent a good strategy to overcome chemoresistance (clinicaltrials.gov: NCT041639000).  349 
Regarding detoxifying enzymes, the high expression of aldehyde dehydrogenase 1 family, member 350 
A3 (ALDH1A3) correlates with a lower response to gemcitabine-based therapy in patients with 351 
advanced iCCA (86), and glutathione S-transferase-pi (GSTP1), also frequently overexpressed in 352 
CCA, has similarly been associated with resistance to cisplatin and other alkylating agents (87). 353 
Downregulation of metallothioneins is accompanied by a better response to cisplatin (88). Other 354 
components involved in mechanisms of chemoresistance include orotate phosphoribosyl transferase 355 
(OPRT), a key enzyme in the activation pathway of 5-FU (89); accordingly, increased expression of 356 
OPRT confers increased sensitivity to 5-FU. By contrast, increased expression of thymidylate 357 
synthase (TS), which is involved in DNA synthesis and normally inhibited by 5-FU metabolites, 358 
results in lower sensitivity to 5-FU (90).  359 
In terms of apoptosis/survival genes, CCA resistance to the EGFR inhibitor erlotinib has been 360 
associated with the upregulation of EGFR in a feedback loop (91). Moreover, increased expression of 361 
the p53-inducible ribonucleotide reductase (p53R2) gene, which is required for normal DNA repair, 362 
correlates with, and has been used to predict, gemcitabine resistance (92). Downregulation of the pro-363 
apoptotic protein NK4, an antagonist of hepatocyte growth factor, is responsible for acquired 364 
resistance to 5-FU in CCA (93), and downregulation of Bax and upregulation of Bcl-2 contribute to 365 
evasion of apoptosis in CCA cells resistant to gemcitabine (94). Furthermore, overexpression of anti-366 
apoptotic proteins such as extracellular signal-regulated kinase (ERK) and Bcl-2, and overactivation 367 
of phosphatidylinositol 3-kinase (PI3K)/AKT and RAF/MEK/ERK pathways have been identified to 368 
be associated with CCA chemoresistance (95).  369 
Changes in the tumour microenvironment, such as hypoxia, extracellular fluid acidification, and the 370 
presence of autocrine and paracrine signals, also affect chemoresistance. Upregulation of the octamer-371 
binding transcription factor 4 (Oct4) in acidic conditions has been shown to be associated with CCA 372 
resistance to gemcitabine (96). Furthermore, the expression of interleukin (IL)-6 and TGF-β1 through 373 
an autocrine loop involving Smad4 has been involved in the resistance to gemcitabine by inducing 374 
epithelial–mesenchymal transition (EMT) (97). Moreover, high expression of the mobility group A1 375 
(HMGA1) protein, which promotes EMT, also confers resistance to gemcitabine (98). In conclusion, 376 
although there continues to be an urgent need to advance our understanding of the mechanisms of 377 
chemoresistance, the situation in CCA is starting to be clarified and novel targets that mediate the 378 
contribution of tumour microenvironment in chemoresitance started to be identified for the 379 
development of therapeutics that could be clinically investigated. 380 
 381 
MicroRNAs as mediators of chemoresistance and potential RNA therapeutics  382 
MicroRNAs (miRNAs or miRs) are single-stranded non-coding RNAs (18–24 nucleotides) that 383 
function as post-transcriptional master regulators to modulate the expression of many genes (99–101). 384 
Altered miRNA profiles have been described in many tissues and cells under pathological 385 
circumstances, including in CCA (101–104), and many miRNAs have been implicated in 386 
chemoresistance in CCA patients. For instance, miR-21 is highly expressed in CCA cells compared 387 
with non-malignant cells, and its experimental inhibition sensitised cells to gemcitabine through the 388 
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inhibition of phosphatase and tensin homolog (PTEN) in vitro and in vivo (105), resulting in 389 
decreased PI3K signalling.  390 
Downregulation of miR-200b/c has been reported in CCA, and its enforced expression restores 5-FU 391 
sensitivity in CCA cells (106). Similarly, miR-29b, miR-205 and miR-221 are downregulated in 392 
gemcitabine-resistant CCA cells, but their experimental overexpression restores gemcitabine 393 
sensitivity (107). The levels of miR-320, which targets the anti-apoptotic protein myeloid cell 394 
leukaemia 1 (MCL1) and contributes to 5-FU resistance, are diminished in iCCA (108). Levels of 395 
miR-106b are reduced in 5-FU-resistant CCA cells, but the experimental overexpression of this 396 
miRNA re-sensitises them to 5-FU, mainly through the modulation of Zbtb7a, a proto-oncogenic 397 
transcription factor (109). miR-130a-3p levels mediate resistance to gemcitabine by targeting the 398 
expression of another transcription factor, peroxisome proliferator-activated receptor (PPARG) (110). 399 
Experimental overexpression of OCT1 in eCCA and iCCA cells enhanced both the uptake and 400 
cytotoxic effects of sorafenib. Notably, miR-141 and miR-330 have been shown to target OCT1 but 401 
the relevance of the modulation of these miRNAs to sorafenib resistance remains to be unveiled (84). 402 
Functional high-throughput approaches combined with analyses of human tissues have identified 403 
miR-1249 as a driver of the expansion of the CD133+ subpopulation that is responsible for primary 404 
and secondary resistance of CCA cells to cisplatin and gemcitabine (104).  405 
As next steps for all these findings, it is imperative to evaluate the relevance of these miRNAs in vivo 406 
and to correlate their levels with resistance to therapy in patients. Although miRNA-based therapies 407 
are already under development, much work needs to be performed in the next few years to improve 408 
strategies to synthesise artificial miRNAs and miRNA inhibitors for clinical implementation. It is 409 
pivotal to develop and improve new delivery techniques that might help to achieve the best 410 
therapeutic efficacy while minimising potential toxic effects.  411 
 412 
Targeting death to improve life  413 
Regulated cell death pathways are central in chronic liver disease progression, where the lack of a 414 
balance between cell death and regeneration has been shown to lead to carcinogenesis (111,112). 415 
Failure of regulated cell death in hepatocytes and cholangiocytes is a pivotal step in malignant 416 
transformation (113). This unique relationship between cell death and liver cancer reflects the 417 
importance of chronic damage and inflammation, with the release of several mediators that have 418 
oncogenic effects. The balance between different types of regulated cell death might influence the 419 
type of liver cancer that eventually develops. For instance, a necroptotic microenvironment with high 420 
cytokine levels can promote cholangiocarcinogenesis by activating specific oncogenes, while an 421 
apoptotic environment appears to increase the risk of hepatocellular carcinogenesis (114). Moreover, 422 
a dysregulated equilibrium between anti-apoptotic and pro-apoptotic signals with evasion of both 423 
intrinsic and extrinsic apoptosis is a key contributor to the resistance of liver cancer to anti-tumour 424 
drugs (115), especially in patients with CCA (116). The apoptotic mitochondrial pathway is 425 
suppressed by overexpression of anti-apoptotic Bcl-2 family proteins, such as Bcl-2 (117) or Mcl-1 426 
(118) in conjunction with downregulation of pro-apoptotic Bcl-2 proteins like Bax (119). Similarly, 427 
impaired caspase activation caused by overexpression of inhibitors of apoptosis proteins (IAPs) such 428 
as XIAP (120) or survivin (83), or abnormal function of death receptors such as Fas (CD95) and 429 
DR4/DR5, contributes to the chemoresistant phenotype in CCA cells.  430 
These mechanisms are also regulated by the surrounding microenvironment (116). Indeed, cancer-431 
associated fibroblasts (CAFs) are key cells that support the growth of liver tumours, and are sensitised 432 
to apoptotic cell death in a characteristic state termed ‘apoptotic priming’ (121). Pro-apoptotic 433 
compounds such as BH3 mimetics are being used to exploit this apoptotic priming with encouraging 434 
results, reducing tumour growth and metastasis in experimental CCA (121). Finally, activation of 435 
necroptosis also seems to play a relevant role in CCA by sensitising cells to standard chemotherapy 436 
(122), suggesting novel necroptosis-based therapeutic strategies for CCA patients. Exploring all these 437 
different mechanisms of regulated cell death will not only help to understand the powerful 438 
mechanisms of chemoresistance but might also reveal novel opportunities for therapeutic intervention. 439 
 440 
Targeting the interaction with the microenvironment  441 
CCA is characterised by marked abundance of tumour stroma, a bioactive connective tissue that not 442 
only physically negatively influences drug delivery, but also cross-talks with cancer cells for the 443 
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activation of a chemoresistant phenotype (123–125). The CCA stroma consists of cancer-associated 444 
endothelial cells, CAFs and inflammatory cells — including tumour-associated macrophages (TAMs), 445 
neutrophils, natural killer (NK) and T cells (126,127) — dispersed in a bioactive specialised 446 
extracellular matrix (ECM) (128). CAFs are mainly responsible for mediating the composition of the 447 
ECM and crosstalk with CCA cells by secreting paracrine factors such as TGF-β and platelet-derived 448 
growth factor (PDGF) (126). Among CCA infiltrating immune cells, TAMs exert a pivotal role in 449 
cancer-related inflammation by promoting tumour-cell proliferation, angiogenesis, matrix turnover 450 
and suppression of the adaptive immune response (129). M2-polarised TAMs communicate in 451 
particular with chemoresistant CCA cancer stem cells by releasing numerous soluble mediators, 452 
including reactive nitrogen intermediates, cytokines (IL-4, IL-6 and IL-10), chemokines (chemokine 453 
ligand (CCL)17 and CCL18) and metalloproteinases [ matrix metalloprotease (MMP)9] (129). 454 
Together, TAMs and CCA cells create a tumoral niche that constitutes a potential target for therapy. 455 
Following the release of CCL2 by tumour cells and TAMs, cytotoxic T lymphocytes acquire 456 
CD4/CD25 expression and become immunosuppressive regulators (Treg cells) (130). By producing 457 
TGF-β and IL-10, Treg cells contribute to an immunosuppressive environment through the inhibition 458 
of cytotoxic T cells and NK cells. Moreover, by selective binding, Treg cells make IL-2 inaccessible, 459 
thus inhibiting the activation of additional immune cells (130). Enrichment of Treg cells has also been 460 
associated with chemoresistance in BTC (131). 461 
As well as cells in the tumour microenvironment, there are other microenvironmental factors linked to 462 
the specialised biomatrix components that can significantly impact the behaviour of cancer cells, such 463 
as hypoxia, exosomes, proliferative factors and inflammatory cytokines (TGF-β; VEGF) (128). All 464 
these factors play different roles in CCA progression and might be considered as potential targets for 465 
therapy. Nevertheless, exploring the dynamics of immunosuppressive cell subpopulations and their 466 
interactions with and within the tumour microenvironment will be essential for a better understanding 467 
of drug resistance and the subsequent design of novel strategies for innovative anti-CCA therapies. 468 
 469 
Novel therapeutic strategies for personalised medicine 470 
 471 
Personalised oncology in BTC 472 
Over the past decade, genomic sequencing technologies (132–135) have helped to shed light on the 473 
molecular landscape of BTCs (51,136). However, despite the remarkable steps taken to unravel the 474 
molecular complexity of this heterogenous disease, the emerging knowledge has only partly been 475 
translated into improved clinical management, and hence further studies are needed. 476 
Retracing the path to precision oncology, Verlingue et al. (136) have demonstrated a tumour-centric 477 
approach based on high-throughput genomic analysis of DNA extracted from tumour biopsy samples, 478 
selecting potential druggable alterations to match the available target treatments in previously treated 479 
BTCs. The prospective MOSCATO-01 trial was successful in determining an outcome improvement 480 
(mOS and PFS) in this cohort compared to patients not oriented to molecular targeted agents (136). 481 
Although preliminary, these results, together with the high frequency of IDH1/2 and FGFR2 genetic 482 
aberrations confirmed in the trial, have laid the foundation for further investigations. However, as a 483 
number of additional targetable molecular alterations have been identified, there is an increasing need 484 
to implement our current genetic profiling technologies in clinical practice in order to tailor therapy 485 
more appropriately in patients with multiple driver aberrations (137). 486 
With this information in mind, in the I-PREDICT prospective study, Sicklick et al. explored the safety 487 
and feasibility of a multidrug combination treatment based on a matching score system combining 488 
actionable molecular alterations with a corresponding available target therapy or therapies. The most 489 
represented population in the study was gastrointestinal refractory tumours (42.2%), including aBTCs. 490 
In this study the ‘matching score’ rate was higher than in previous studies, with 49% of patients 491 
receiving multidrug regimens. The highest matching score rate was associated with significantly 492 
improved disease control rates, as well as longer PFS and OS rates, compared with patients receiving 493 
therapy matched to fewer genomic alterations (138). Therefore, the current clinical trial paradigm, 494 
focused on finding common genomic alterations in patients and targeting them with a single agent, 495 




Novel strategies to implement individualisation of treatment: liquid biopsies and patient-derived 499 
models  500 
Up to 50% of BTCs are expected to be eligible for targeted therapies and it has therefore been 501 
suggested that genomic profiling is incorporated in routine clinical practice. One of the limiting issues 502 
for implementing personalised oncology in BTCs is the lack of tissue for molecular analyses, 503 
especially for those BTCs that are diagnosed through cytological sampling. However, this issue might 504 
be overcome by the use of liquid biopsies. Mody et al.(139) presented their experience with a targeted 505 
next-generation sequencing panel of 73 genes from the plasma of >120 patients with aBTC. The 506 
assessment of molecular alterations was feasible in cell-free DNA (cfDNA) and identification of 507 
therapeutically relevant alterations was also successful (BRAF and IDH1/2 mutations, ERBB2 508 
amplification, FGFR2 fusions). The limitation of this study was the preponderance of iCCA cases in 509 
this cohort, for which lack of tissue is not usually a problem (139). Preliminary evidence from only 10 510 
patients has demonstrated the possibility of using bile as a source for deep DNA sequencing, showing 511 
that cfDNA in bile consists of longer fragments than cfDNA in plasma (with potential higher quality 512 
of DNA sequencing) and that there is high correspondence between the mutational profile in bile and 513 
BTC tissue (140). Further studies are warranted to assess whether bile might be a suitable source of 514 
cfDNA for use in the implementation of personalised oncology in patients with advanced pCCA and 515 
dCCA. Circulating tumour cells (CTC) are an alternative approach, but to date low levels of CTC 516 
have been detected in BTC limiting their clinical applicability (141). 517 
DNA sequencing can support precision oncology by identifying targetable molecular alterations. 518 
However, it is of no help for guiding treatment decisions in the case of drugs for which predictive 519 
biomarkers have not been identified, such as chemotherapy compounds or multityrosine kinases. 520 
Patient-derived xenografts (PDXs) have been used for this purpose but their clinical applicability may 521 
be limited by costs and timeframe (142). Patient-derived organoids (PDOs) are ex vivo, organ-like, 522 
three-dimensional structures derived from individual patient cells that could be used to predict 523 
response to compounds independently on the presence of a molecular biomarker. Notably, cancer 524 
PDOs mimic the structure and genomic heterogeneity of their host tumours (143) and have been 525 
demonstrated to mimic in a dish the drug response observed in patients (144), generating excitement 526 
on the potential use of these PDOs as predictive tools. Growing evidence is supporting the feasibility 527 
of establishing  biliary cancer PDOs. However, the success rate for generating PDOs from different 528 
subtypes of biliary cancer is not yet clear, and so more studies are warranted before this approach can 529 
be used to support individualised oncology in patients with BTCs. The next key steps to validate and 530 
promote the use of organoids as clinically relevant tools for the study of biliary cancers include the 531 
generation of characterised models representing the different CCA subtypes (intrahepatic, perihilar 532 




The current guidelines indicate the use of first line chemotherapy with cisplatin and gemcitabine in 537 
aBTC, followed by FOLFOX chemotherapy. Novel targeted therapies (IDH and FGFR inhibitors) are 538 
being considered for iCCA with selected molecular alterations. An ever-increasing number of 539 
molecular alterations is being identified, with different BTC subtypes showing specific molecular 540 
profiles. Beyond the role of standard chemotherapy, this approach paves the way to design molecular-541 
oriented clinical trials in which different BTC subtypes can be matched to different targeted 542 
inhibitors. One common difficulty encountered when studying rare diseases is the low number of 543 
cases that can be investigated in a single institution, and this was indeed the case for BTCs until 544 
international CCA-dedicated associations were established, with contributions from both basic and 545 
clinical researchers in an attempt to join efforts, skills, information, and biological samples to improve 546 
research in CCA. Although the situation regarding the available therapeutic options in BTC patients is 547 
still limited at present, the increased interest in CCA research and the rapidly growing amount of 548 
information in the field support a more optimistic horizon in the near future.  549 
 550 
 551 
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Figure legend 617 
 618 
Figure 1. Schematic representation of the molecular mechanisms of chemoresistance, of which there 619 
are seven depicted (77–79). (1) Changes in the expression/function of transport proteins involved in 620 
drug uptake  or efflux. (2) A reduction in the intracellular amount of active drugs due to changes in 621 
enzymes involved in metabolism. (3) Changes in the molecular targets of anticancer agents. (4) An 622 
increased ability of tumour cells to repair drug-induced DNA damage. (5) Decreased 623 
expression/function of pro-apoptotic factors or enhanced expression/function of anti-apoptotic 624 
proteins. (6) Changes in tumour cell microenvironment conditions that affect the effectiveness of 625 
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Table 1. Inhibitors of IDH1/2 and FGFR2 fusions: current clinical trials 2 
aCCA advanced cholangiocarcinoma, iCCA intrahepatic cholangiocarcinoma, PFS progression-free 3 
survival, OS overall survival, DCR disease control rate, DOR duration of response, ORR overall 4 
response rate, PR partial response, CR complete response, SD stable disease, CBR clinical benefit 5 

























I PFS ORR,  DoR, DCR,  AE, QoL 






I PFS OS,  ORR, DOR, DCR, AE 






OS,  Safety and 
tolerability 






II ORR PFS , DOR, DCR, OS 





II PFS at 3 months 
EORTC QLQ-C30, 
OS, DOR 
NCT02150967 2 FGFR Infigratinib FGFR alterations aCCA II ORR PFS, OS, DCR 
NCT02052778 1/2 FGFR Futibatinib (TAS-120) 
FGFR Aberrations 
CCA II ORR PFS, OS, DCR 
NCT04238715 2 FGFR2 E7090 FGFR2 gene fusions aCCA II ORR 
PFS, DOR, TTR, 




2 FGRF Erdafitinib FGFR alterations aCCA II ORR PFS, OS, DCR 







AE, PFS, TTP, 
DOR, OS 
NCT03212274 2 PARP Olaparib IDH1 or IDH2  mutant CCA II ORR PFS, OS, DoR 





IDH1 and IDH2 
mutant CCA 
 
II ORR PFS, OS, DOR, AE 
 1
 1 
Table 2. Novel opportunities for targeted therapeutics in biliary cancers: ongoing clinical trials 2 
aBTC advanced biliary tract cancer, aCCA advanced cholangiocarcinoma, PFS progression-free 3 
survival, OS overall survival, DCR disease control rate, DOR duration of response, ORR overall 4 
response rate, PR partial response, CR complete response, SD stable disease, CBR clinical benefit 5 
rate, TTR time to response, AE adverse events, QoL quality of life, DDR DNA damage response, 6 
DLT dose-limiting toxicity, TAA tumour-associated antigen, RP2D recommended phase II dose, 7 


























































































































M7824 aBTC II ORR 




1 TAA AG7 AbGn-107 aBTC II AE, safety 
Pharmacokinetics, 
pharmacodynamics 
NCT02576431 2 NTRK Larotrectinib 
NTRK fusions 
aBTC 
II ORR PFS, OS, DoR 





II ORR PFS, DoR, TTR 





II ORR PFS, OS, DoR 









NCT03873532 2/3 MAPK Surufatinib aBTC II OS PFS, DCR, DoR 





Table 3. Targetable mutations in CCA 4 
GBC gallbladder cancer, iCCA intrahepatic cholangiocarcinoma, eCCA, extrahepatic 5 
cholangiocarcinoma.ESCAT: ESMO Scale for Clinical Actionability of molecular Targets. DDR: 6 















Incidence Primary tumour site Possible agents ESCAT 
 
‘Established’ 


















IDH1 mutation 10% iCCA Ivosidenib (41) FT-1202 I-B 
 














MSI-H 1-3% eCCA/iCCA/GBC Durvalumab Pembrolizumab II-B 
BRAF V600E mutation 3% eCCA/iCCA/GBC Dabrafenib-trametinib (66) III-A 
BRCA2 mutation 3% eCCA/iCCA/GBC Olaparib (67) III-A 
EGRF 
mutation/amplification 3% eCCA/iCCA/GBC Osimertinib III-A 
‘Experimental’ targets 
and drugs 
BRAF non V600E 
mutation 1.5% eCCA/iCCA/GBC 
Encorafenib-
Binimetinib IV-A 




10 % eCCA/iCCA/GBC Olaparib IV-A 
EGFR amplification <5% eCCA/iCCA/GBC Osimertinib (61) IV-A 
NTRK fusions/ROS1 < 5% eCCA/iCCA/GBC Larotrectinib -Entrectinib IV-A 
PIK3CA mutation < 10% eCCA/iCCA/GBC Everolimus-Sirolimus IV-A 
 1
Table 4. Immunotherapy combinations: ongoing clinical trials  1 
Combinations of immunotherapy with chemotherapy and other agents.  2 
PFS progression-free survival, OS overall survival, DCR disease control rate, ORR overall response 3 
rate, PR partial response, CR complete response, SD stable disease, DOR duration of response, CBR 4 
clinical benefit rate, DLT dose-limiting toxicities, MTD maximum tolerated dose, AE adverse events, 5 
PARP poly-ADP ribose polymerase, GEMOX gemcitabine + oxaliplatin, GEM/CIS gemcitabine + 6 
cisplatin, FOLFOX fluorouracil + folinic acid + oxaliplatin. 7 
 8 
 2




















































AE ORR, OS 


























Durvalumab or Placebo 
and GEM/CIS 









aBTC I RR 
DCR, PFS, 
DoR, OS 
NCT02834013 2 PD-1, CTLA-4 
Nivolumab/ 
Ipilimumab 






















OS, PFS, DCR, 
DoR 
NCT04211168 2 PD-1, VEGF 
Toripalimab/ 
Lenvatinib 
aBTC II ORR, AEs 
OS, PFS, OS, 
CBR 



























GEM/CIS with or 
without Bintrafusp Alfa 
(M7824) 




NCT03937895 1/ 2 PD-1, SMT-NK 
Pembrolizumab/ 
Allogeneic NK Cell 
aBTC II DLT, ORR TTP, toxicity 













aBTC II ORR PFS, OS, DoR 







CR, PR, SD, 
PFS, OS 






















NCT03475953 1/ 2 PD-1, MAPK 
Avelumab/ 
Regorafenib 
Metastat
ic solid 
tumours 
I/II 
RP2D, 
antitumour 
activity 
MTD, DLT, 
toxicity 
 3
 9 

